Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis.
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
Decreased microglial activation in MS patients treated with glatiramer acetate.
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
National Cancer Institute Search for Clinical Trials
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Cognitive impairment in multiple sclerosis.
Biogen Reports Another Tecfidera PML Case
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
European Medicines Agency
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
Generic interferon-beta
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.

Pages